Correction to: Osteoporosis International (2019) 30:1175–1186
The original version of this article, published on February 7, 2019, contained a mistake.
The correct information is given below. The original article has been corrected.
Results - Efficacy evaluations - Menatetrenone versus placebo/no additional drug:
“In addition, analysis of four studies [22,24,26,38] (N=356) revealed a significantly greater percent increase in lumbar BMD from baseline for menatetrenone compared with placebo or no additional anti-osteoporotic drug (MD=2.02%, 95% CI 1.05 to 2.99%, P <0.0001) (Fig. 3 and Online Resource 3).”
Table 1 . Characteristics of the included RCTs
In the “Outcome” column, the Orimo 1999 study should be “9,12,13” rather than “5,9,12,13”.
Correction in supplementary material
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00198-019-04853-7
Rights and permissions
About this article
Cite this article
Su, S., He, N., Men, P. et al. Correction to: The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 32, 2141–2142 (2021). https://doi.org/10.1007/s00198-021-06053-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-021-06053-8